iECURE
Eric Squinto is a professional with extensive experience in market development, strategy, and business operations within the biotechnology and healthcare sectors. Since April 2024, Eric has held the position of Manager, Market Development & Intelligence at iECURE, inc. Prior roles include Manager of Strategy & Business Operations at Gennao Bio from May 2021 to May 2024 and Associate of Business Development at Chardan from May 2019 to May 2021. Eric's earlier career includes significant roles at Havas Health & You and Burst.it, LLC, demonstrating expertise in account management, project management, and team collaboration. Educational credentials include a Bachelor of Science degree in Economics from Northeastern University, completed in 2014.
This person is not in any teams
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.